<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Morse LR</submitter><funding>Craig H. Neilsen Foundation</funding><pagination>e1301</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12173286</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(4)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9-10/10) spinal cord injury-related neuropathic pain.&lt;h4>Methods&lt;/h4>We conducted a multisite pilot study where adults were randomized to 3 months of brivaracetam (100 mg BID) or placebo. Pain was assessed via the Brief Pain Inventory, the International Spinal Cord Injury Pain Basic Dataset (version 2.0), and a daily pain diary.&lt;h4>Results&lt;/h4>We enrolled 24 participants across 2 sites and 14 participants were included in the final analysis (n = 8 placebo, n = 6 brivaracetam). The drug was tolerated with expected, nonserious side effects (nausea if taken on an empty stomach, fatigue that improved after 2-3 days). Side effects were more common in the brivaracetam group (73%, n = 8 vs </pubmed_abstract><journal>Pain reports</journal><pubmed_title>Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.</pubmed_title><pmcid>PMC12173286</pmcid><funding_grant_id>652052</funding_grant_id><pubmed_authors>Anderton G</pubmed_authors><pubmed_authors>Goldstein R</pubmed_authors><pubmed_authors>Wudlick R</pubmed_authors><pubmed_authors>DeVries B</pubmed_authors><pubmed_authors>Nguyen N</pubmed_authors><pubmed_authors>Stillman M</pubmed_authors><pubmed_authors>Battaglino RA</pubmed_authors><pubmed_authors>Falci SP</pubmed_authors><pubmed_authors>Welch A</pubmed_authors><pubmed_authors>Linnman C</pubmed_authors><pubmed_authors>Glossner J</pubmed_authors><pubmed_authors>Morse LR</pubmed_authors><pubmed_authors>Battaglino AL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.</name><description>&lt;h4>Objective&lt;/h4>Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9-10/10) spinal cord injury-related neuropathic pain.&lt;h4>Methods&lt;/h4>We conducted a multisite pilot study where adults were randomized to 3 months of brivaracetam (100 mg BID) or placebo. Pain was assessed via the Brief Pain Inventory, the International Spinal Cord Injury Pain Basic Dataset (version 2.0), and a daily pain diary.&lt;h4>Results&lt;/h4>We enrolled 24 participants across 2 sites and 14 participants were included in the final analysis (n = 8 placebo, n = 6 brivaracetam). The drug was tolerated with expected, nonserious side effects (nausea if taken on an empty stomach, fatigue that improved after 2-3 days). Side effects were more common in the brivaracetam group (73%, n = 8 vs </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-06-02T22:29:50.219Z</modification><creation>2026-04-21T03:13:46.043Z</creation></dates><accession>S-EPMC12173286</accession><cross_references><pubmed>40528843</pubmed><doi>10.1097/PR9.0000000000001301</doi></cross_references></HashMap>